Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00090753 · ClinicalTrials.gov registry record · Phase 3
A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,228
- Enrollment target
NCT00090753 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 1,228 participants.
The verdict
NCT00090753, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,228 participants
- Enrollment target
Study Summary
This study assessed the long-term efficacy, safety, and tolerability of intravenous (iv) or subcutaneous (sc) methoxy polyethylene glycol-epoetin beta in chronic kidney disease patients with renal anemia. Eligible patients were those who were receiving stable maintenance therapy with methoxy polyethylene glycol-epoetin beta or erythropoiesis stimulating agents (ESAs) in Phase II or III clinical studies. They continued to receive methoxy polyethylene glycol-epoetin beta or comparator ESAs at the same weekly dose and by the same route of administration (sc or iv) as in the qualifying studies.
Interventions
- DRUG Epoetin alfa
- DRUG Darbepoetin alfa
- DRUG Methoxy Polyethylene Glycol-Epoetin Beta
- DRUG Epoetin beta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,228 participants |
| Start Date | 2004-10 |
| Est. Completion | 2009-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00090753
The ClinicalTrials.gov registry entry for NCT00090753 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,228 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Epoetin alfa is the first listed.
NCT00090753 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00090753 about?
NCT00090753 is a clinical study titled "A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia". This study assessed the long-term efficacy, safety, and tolerability of intravenous (iv) or subcutaneous (sc) methoxy polyethylene glycol-epoetin beta in chronic kidney disease patients with renal anemia. Eligible patients were those who were receiving stable maintenance therapy with methoxy polyeth...
What is the current status of trial NCT00090753?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,228 participants. The study started on 2004-10. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00090753?
The interventions under investigation include: Epoetin alfa (DRUG), Darbepoetin alfa (DRUG), Methoxy Polyethylene Glycol-Epoetin Beta (DRUG), Epoetin beta (DRUG).
Who is sponsoring clinical trial NCT00090753?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.